Roth Capital Reiterates $10.00 Price Target for Anavex Life Sciences (AVXL)

Roth Capital set a $10.00 target price on Anavex Life Sciences (NASDAQ:AVXL) in a research report released on Friday morning. The firm currently has a buy rating on the biotechnology company’s stock.

Other analysts also recently issued research reports about the company. Maxim Group set a $7.00 price objective on Anavex Life Sciences and gave the stock a buy rating in a report on Thursday, December 13th. HC Wainwright set a $10.00 target price on Anavex Life Sciences and gave the company a buy rating in a report on Wednesday, October 31st. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus target price of $7.40.

NASDAQ AVXL opened at $2.39 on Friday. The stock has a market cap of $112.07 million, a price-to-earnings ratio of -6.13 and a beta of 2.41. Anavex Life Sciences has a 1 year low of $1.25 and a 1 year high of $4.35.

Anavex Life Sciences (NASDAQ:AVXL) last posted its quarterly earnings data on Thursday, February 7th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.03). Equities analysts expect that Anavex Life Sciences will post -0.46 earnings per share for the current year.

Several institutional investors and hedge funds have recently modified their holdings of the company. Millennium Management LLC acquired a new position in shares of Anavex Life Sciences in the 2nd quarter valued at about $1,749,000. Hikari Power Ltd acquired a new position in shares of Anavex Life Sciences in the 4th quarter valued at about $231,000. Finally, Jane Street Group LLC acquired a new position in shares of Anavex Life Sciences in the 2nd quarter valued at about $157,000. Institutional investors own 17.88% of the company’s stock.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system diseases. The company's lead drug candidate is ANAVEX 2-73, which has completed Phase 2a clinical trial for Alzheimer's disease; and preclinical clinical trials to treat Parkinson's disease, Rett syndrome, epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis.

Featured Story: Stock Selection – What is cash flow?

Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply